Welcome to our dedicated page for Verona Pharma plc news (Ticker: VRNA), a resource for investors and traders seeking the latest updates and insights on Verona Pharma plc stock.
Verona Pharma plc (VRNA) is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for respiratory diseases that have significant unmet medical needs. Headquartered in both the United States and the United Kingdom, Verona Pharma is publicly traded on the NASDAQ Global Market and the London Stock Exchange.
The company's flagship product, Ensifentrine, is currently in development for the treatment of chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF). Ensifentrine is a dual inhibitor that has demonstrated potential in reducing inflammation and relaxing airway muscles, addressing critical gaps in the treatment of these chronic diseases. In addition to COPD and CF, Verona Pharma aims to expand its therapeutic pipeline to include treatments for other respiratory conditions such as asthma.
Verona Pharma's success is underpinned by a team of seasoned experts with extensive backgrounds in the discovery, development, and commercialization of respiratory therapies. The company has also forged strong partnerships with leading research institutions and advocacy organizations in the respiratory health sector. These collaborations have been instrumental in advancing their clinical programs and have garnered Verona Pharma several awards for innovation.
Recent achievements include the successful completion of Phase 2 clinical trials for Ensifentrine, which showed promising results in improving lung function and reducing symptoms in COPD patients. The company is now steering towards Phase 3 trials, marking a significant milestone in its mission to bring effective treatments to market.
Financially, Verona Pharma has demonstrated stability and growth, strengthening its financial flexibility through strategic funding rounds. This robust financial health supports ongoing research and development activities, ensuring sustained progress in their clinical programs. The company’s near-term goals include advancing Ensifentrine into late-stage clinical trials and exploring potential marketing authorizations.
For the latest updates on Verona Pharma’s research, financial performance, and upcoming milestones, stay tuned to the latest news and press releases.
Verona Pharma (Nasdaq: VRNA) announces its participation in two major healthcare investor conferences in December 2024. The company will present at the Piper Sandler 36th Annual Healthcare Conference in New York on December 3 at 12:00 p.m. ET, and at the 7th Annual Evercore HealthCONx Conference in Miami on December 4 at 3:00 p.m. ET. Webcasts of both presentations will be available on the company's website. Verona Pharma specializes in developing therapies for chronic respiratory diseases, with their first commercial product Ohtuvayre™ (ensifentrine) being a dual-action COPD treatment.
Verona Pharma (Nasdaq: VRNA) announces its participation in the upcoming Jefferies London Healthcare Conference. The company's senior management will deliver a company overview on Tuesday, November 19, 2024, at 6:30 a.m. ET / 11:30 a.m. GMT.
A webcast of the presentation will be accessible through the Events and Presentations section on the Investors page of Verona Pharma's website. The company has provided contact information for investor relations, US investor enquiries, and international/US media enquiries for those seeking additional information.
Verona Pharma reported strong Q3 2024 results, with Ohtuvayre™ (ensifentrine) launch generating $5.6 million in net sales during its first seven weeks. October sales exceeded Q3 performance, with over 5,000 prescriptions filled and 2,200 unique prescribers across COPD patients. The company initiated two Phase 2 trials: a dose-ranging trial with glycopyrrolate and a trial for non-cystic fibrosis bronchiectasis. Cash position stood at $336.0 million, expected to fund operations through 2026. Q3 expenses increased with R&D at $10.6 million and SG&A at $35.2 million, resulting in a net loss of $43.0 million.
Verona Pharma plc (Nasdaq: VRNA) has announced it will report its financial results for the third quarter ended September 30, 2024 on Monday, November 4, 2024. The company will also host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. GMT to discuss these financial results and provide a corporate update.
To participate in the call, investors can dial +1-833-816-1396 (US callers) or +1-412-317-0489 (international callers) and ask to join the Verona Pharma call. A live webcast will be available on the Events and Presentations link on the Investors page of the company's website, www.veronapharma.com, with an audio replay available for 90 days.
Verona Pharma announces six analyses from its Phase 3 ENHANCE studies with Ohtuvayre (ensifentrine) for COPD treatment to be presented at CHEST 2024. The presentations include four oral and two poster sessions, highlighting Ohtuvayre's efficacy and safety in various COPD patient subgroups. Key findings show improvements in lung function, symptoms, and quality of life, as well as reduced exacerbation rates, regardless of COPD severity, smoking status, or chronic bronchitis presence.
Ohtuvayre, a first-in-class dual inhibitor of PDE3 and PDE4, combines bronchodilator and anti-inflammatory effects. It's the first novel inhaled mechanism for COPD maintenance treatment in over 20 years. The analyses will also present data on Ohtuvayre's impact on reducing COPD-related healthcare resource utilization over 48 weeks.
Ritedose, the largest CDMO in the US specializing in sterile Blow Fill Seal production, has partnered with Verona Pharma (Nasdaq: VRNA) to develop and manufacture Ohtuvayre (ensifentrine), a novel COPD treatment. The FDA approved Ohtuvayre on June 26 for maintenance treatment of COPD in adults, marking the first inhaled product with a new mechanism of action in over 20 years. Ohtuvayre, delivered via standard jet nebulizer, is a first-in-class PDE3 and PDE4 inhibitor that aims to redefine COPD treatment. With COPD affecting over 480 million people globally and 14 million in the US, this partnership between Ritedose and Verona Pharma brings a significant advancement to the respiratory market.
Verona Pharma (Nasdaq: VRNA) announces presentations of additional analyses from its Phase 3 ENHANCE studies on Ohtuvayre™ (ensifentrine) for COPD treatment at the ERS International Congress 2024. The presentations include one oral and three posters, highlighting Ohtuvayre's efficacy and safety in various COPD patient subgroups.
Ohtuvayre, a first-in-class dual inhibitor of PDE3 and PDE4, combines bronchodilator and anti-inflammatory effects. Key findings include improvements in lung function, reduced exacerbation rates, and enhanced quality of life across different patient populations. The analyses support Ohtuvayre's potential to benefit a broad range of COPD patients, marking the first novel inhaled mechanism for COPD maintenance treatment in over 20 years.
Verona Pharma (NASDAQ: VRNA) announced that Ohtuvayre (ensifentrine) is now available in the US for COPD maintenance treatment. Key highlights:
- Over 2,000 HCP visits conducted and 100+ unique HCPs have prescribed Ohtuvayre
- Submitted IND for ensifentrine-glycopyrrolate combination therapy
- Plans to initiate Phase 2 trial for non-cystic fibrosis bronchiectasis in Q3 2024
- Cash position of $404.6 million as of June 30, 2024
- Q2 2024 R&D expenses increased to $19.4 million (Q2 2023: -$2.5 million)
- Q2 2024 SG&A expenses rose to $49.0 million (Q2 2023: $12.4 million)
- Q2 2024 net loss of $70.8 million (Q2 2023: $8.8 million loss)
The company believes its current cash position will fund operations beyond 2026, including Ohtuvayre's US commercial launch.
Verona Pharma (Nasdaq: VRNA) has announced its participation in the 44th Annual Canaccord Growth Conference. The company's senior management will present a company overview on Tuesday, August 13, 2024, at 1:30 p.m. EDT / 6:30 p.m. BST.
Investors and interested parties can access a webcast of the event through the Events and Presentations link on the Investors page of Verona Pharma's website, www.veronapharma.com. This presentation provides an opportunity for the company to showcase its progress and future plans to a wider audience of potential investors and industry professionals.
For those seeking additional information, Verona Pharma has provided contact details for investor relations, US investor enquiries, and international/US media enquiries.
Verona Pharma plc (Nasdaq: VRNA) has announced it will report its financial results for the second quarter ended June 30, 2024, on Thursday, August 8, 2024. The company will also host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update.
To participate in the call, investors can dial +1-833-816-1396 (US callers) or +1-412-317-0489 (international callers) and ask to join the Verona Pharma call. A live webcast will be available on the Events and Presentations link on the Investors page of the company's website, with an audio replay accessible for 90 days.
FAQ
What is the current stock price of Verona Pharma plc (VRNA)?
What is the market cap of Verona Pharma plc (VRNA)?
What is Verona Pharma plc?
What is Ensifentrine?
What diseases does Verona Pharma target?
Where is Verona Pharma listed?
Who leads Verona Pharma?
What recent achievements has Verona Pharma made?
What are Verona Pharma’s near-term milestones?
Does Verona Pharma have any partnerships?
What awards has Verona Pharma received?
How can I stay updated on Verona Pharma?
